The PAH treatment market is expected to grow from USD 5,811.5 million in 2023 to USD 7,224.4 million by 2033, at a CAGR of ...

Among patients with pulmonary arterial hypertension treated with 72-week seralutinib, those deemed responders had more improved measures, according to a poster presented at the Pulmonary Vascular ...

umcg.nl Pulmonary arterial hypertension (PAH) in congenital heart disease (CHD) can be reversed by early shunt closure, but this potential is lost beyond a certain point of no return. Therefore, it is ...

Great dividend stocks should offer a mix of durability, solid income generation, and growth prospects. Read more to see 2 ...

11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study.

Following an admission to the authors’ centre with severe anaemia, duodenal biopsy confirmed the diagnosis of Whipple’s ...

The immune protein STAT6 may be a driver of pulmonary hypertension in people with obstructive sleep apnea, a study in mice ...

Department of Therapeutic Strategy for Heart Failure, Tokyo, Japan 3 Graduate School of Medicine, The University of Tokyo, Department of Allergy and Rheumatology, Tokyo, Japan Background: Connective ...

The Aeson Total Artificial Heart helped three people with heart failure and pulmonary hypertension become eligible for a ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Lungpacer Medical today announced positive results from a Phase 1 clinical study evaluating its neurostimulation technology ...